proposed the so-called Metroticket 2.0 model, which was constructed to predict post-transplant HCC-related specific death by considering AFP as a surrogate marker of microvascular invasion and morphological characteristics of HCC [29]. The gene discussed is AFP; the disease is hepatocellular carcinoma.